Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa double-blind placebo-controlled trial of CG-BM1 allogeneic human bone marrow mesenchymal stem cell injection for ischemic stroke
CTR20252410Phase 2Active
- Sponsor
- Saijun Biotech
- Start
- Aug 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of CG-BM1 in ischemic stroke, sponsored by Saijun Biotech. Started Aug 2025; status: active.
02
Drugs
CG-BM1
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20252410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252410.